Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.

PLoS One · 2019 · PMC6326518 · PMID 30625226

Europe PMC DOI

hedged sentences

0.0198

closest p · 0.4× alpha

0.0716

boldest claim

The sentences

highly significantp = 0.0198actually significant

The efficacy of combination therapy was highly significant when compared to ABT-737 (p = 0.0198) and 9.2.27-PE38KDEL monotherapies (p = 0.0100; Fig 5A ).

also in 132,142 other papers

failed to reach statistical significancep = 0.0716so close (0.05 < p ≤ 0.1)

The 9.2.27-PE38KDEL (0.1 μg) monotherapy exhibited a modest 10.7% increase in MS compared to the control but failed to reach statistical significance (p = 0.0716).

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.